Stock Analysis, Dividends, Split History

CVCO / Cavco Industries, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,056.64
Enterprise Value ($M)1,967.65
Book Value ($M)457.11
Book Value / Share52.46
Price / Book4.39
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 9,044,858
Common Shares Outstanding 9,044,943
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.12
Return on Assets (ROA)0.10
Return on Equity (ROE)0.16
Balance Sheet (mrq) ($M)
Quick Ratio1.75
Current Ratio2.44
Income Statement (mra) ($M)
Sales Revenue Net871,235,000.00
Operating Income73.77
Net Income61.50
Earnings Per Share Basic6.82
Earnings Per Share Diluted6.68
Cash Flow Statement (mra) ($M)
Cash From Operations58.77
Cash from Investing-4.67
Cash from Financing-4.67
Identifiers and Descriptors
Central Index Key (CIK)278166
Related CUSIPS
Industry Groups
SIC 2451 - Mobile Homes

Split History

Stock splits are used by Cavco Industries, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

Cavco Industries, Inc. (CVCO) CEO Joseph Stegmayer on Q1 2019 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the First Quarter and Fiscal Year 2019 Cavco Industries Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Joe Stegmayer, Chairman and CEO. Sir, you may begin.

Buy These 7 Small-Cap Stocks for Their Emerging Opportunities

2018-06-04 investorplace
Both the Russell 2000 and S&P 600 indices hit all-time highs last week as investors continued to jump on the small-cap bandwagon. Can anything stop small-cap stocks from moving higher over the remainder of 2018? (47-2)

Cavco Industries' (CVCO) CEO Joe Stegmayer on F4Q 2018 Results - Earnings Call Transcript

2018-05-30 seekingalpha
Cavco Industries, Inc. (NASDAQ:CVCO) F4Q 2018 Results Earnings Conference Call May 30, 2018 11:00 PM ET (4-0)

CUSIP: 149568107